➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
McKinsey
Boehringer Ingelheim
Express Scripts

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for RPL554


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug RPL554?

RPL554 is an investigational drug.

There have been 10 clinical trials for RPL554. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and LGC Limited.

There are eleven US patents protecting this investigational drug and one hundred and seventy-four international patents.

Recent Clinical Trials for RPL554
TitleSponsorPhase
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDIQVIAPhase 2
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDLGC LimitedPhase 2
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDVerona Pharma plcPhase 2

See all RPL554 clinical trials

Clinical Trial Summary for RPL554

Top disease conditions for RPL554
Top clinical trial sponsors for RPL554

See all RPL554 clinical trials

US Patents for RPL554

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RPL554   Start Trial Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
RPL554   Start Trial Chemical compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
RPL554   Start Trial Derivatives of pyrimido[6.1-a]isoquinolin-4-one Vernalis Limited (Berkshire, GB)   Start Trial
RPL554   Start Trial Derivatives of pyrimido[6,1-a]isoquinolin-4-one Rhinopharma Limited (British Columbia, CA)   Start Trial
RPL554   Start Trial Derivatives of pyrimido[6, 1-A]isoquinolin-4-one Verona Pharma PLC (London, GB)   Start Trial
RPL554   Start Trial Derivatives of pyrimido[6,1-A]isoquinolin-4-one Verona Pharma plc (London, GB)   Start Trial
RPL554   Start Trial Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound Verona Pharma plc (London, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RPL554

Drugname Country Document Number Estimated Expiration Related US Patent
RPL554 Argentina 099177 2034-01-24   Start Trial
RPL554 Australia 2015208932 2034-01-24   Start Trial
RPL554 Australia 2017200338 2034-01-24   Start Trial
RPL554 Australia 2018202956 2034-01-24   Start Trial
RPL554 Australia 2019202675 2034-01-24   Start Trial
RPL554 Canada 2935625 2034-01-24   Start Trial
RPL554 Chile 2016001889 2034-01-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.